DK2310510T3 - IDNA-vacciner og fremgangsmåder til deres anvendelse - Google Patents

IDNA-vacciner og fremgangsmåder til deres anvendelse Download PDF

Info

Publication number
DK2310510T3
DK2310510T3 DK09798313.4T DK09798313T DK2310510T3 DK 2310510 T3 DK2310510 T3 DK 2310510T3 DK 09798313 T DK09798313 T DK 09798313T DK 2310510 T3 DK2310510 T3 DK 2310510T3
Authority
DK
Denmark
Prior art keywords
idna
vaccine
virus
rna
dna
Prior art date
Application number
DK09798313.4T
Other languages
English (en)
Inventor
Peter Pushko
Igor Lukashevich
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Application granted granted Critical
Publication of DK2310510T3 publication Critical patent/DK2310510T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1
1. Plasm idvektor, omfattende: (a) en RNA-polymerasefremmer, som er virksomt forbundet med en DNA, 5 der koder et infektiøst RNA-molekyle, og (b) en poly-A-hale nedstrøms for nævnte DNA, hvori (i) RNA-molekylet koder en svækket gul feber (YF) virus, og (ii) RNA-polymerasefremmeren er egnet til eksprimering i pattedyrsceller. 10
2. Vektor ifølge krav 1, hvori fremmeren er placeret fra ca. 12 til ca. 18 nukleoti-der opstrøms for 5’-enden for nævnte DNA.
3. Vektor ifølge krav 2, hvori fremmeren er placeret 15 nukleotider opstrøms for 15 5’-enden af nævnte DNA.
4. Vektor ifølge ethvert foregående krav, hvori poly-A-halen er placeret fra 0 til 500 nukleotider nedstrøms for nævnte DNA.
5. Vektor ifølge ethvert foregående krav, hvori fremmeren er en CMV-RNA- polymerasefremmer.
6. Vektor ifølge ethvert foregående krav, hvori nævnte DNA, der koder RNA-molekylet, omfatter en YF17D cDNA (nukleotider 703 til 11564 i Figur 8) eller en 25 polynukleotidsekvens med mindst 95% sekvensidentitet med nævnte YF17D cDNA over sidstnævntes samlede længde.
7. Vaccine omfattende en terapeutisk effektiv mængde af vektoren ifølge ethvert af de foregående krav. 30
8. Vaccine ifølge krav 7, yderligere omfattende en farmaceutisk acceptabel bærer.
9. Vaccine ifølge krav 7 eller 8 til anvendelse ved immunisering af et pattedyr mod en YF virus. 35
10. Vaccine til anvendelse ifølge krav 9, hvori pattedyret er et menneske.
DK09798313.4T 2008-07-17 2009-07-17 IDNA-vacciner og fremgangsmåder til deres anvendelse DK2310510T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8148208P 2008-07-17 2008-07-17
PCT/US2009/004133 WO2010008576A2 (en) 2008-07-17 2009-07-17 Idna vaccines and methods for using the same

Publications (1)

Publication Number Publication Date
DK2310510T3 true DK2310510T3 (da) 2015-08-03

Family

ID=41550920

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15166439.8T DK2977457T3 (da) 2008-07-17 2009-07-17 Idna-vacciner og fremgansmåder til anvendelse af disse
DK09798313.4T DK2310510T3 (da) 2008-07-17 2009-07-17 IDNA-vacciner og fremgangsmåder til deres anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15166439.8T DK2977457T3 (da) 2008-07-17 2009-07-17 Idna-vacciner og fremgansmåder til anvendelse af disse

Country Status (6)

Country Link
US (3) US8691563B2 (da)
EP (3) EP3992296A1 (da)
BR (1) BRPI0916186B8 (da)
DK (2) DK2977457T3 (da)
ES (2) ES2544702T3 (da)
WO (1) WO2010008576A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544702T3 (es) * 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
US10602508B2 (en) * 2015-08-10 2020-03-24 Qualcomm Incorporated LTE-direct communication for vehicle-to-vehicle
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
ATE276271T1 (de) * 1998-03-27 2004-10-15 Secr Defence Rekombinantes virus
FR2779736B1 (fr) 1998-06-12 2002-12-13 Goemar Lab Sa Genes codant pour des beta-agarases et leur utilisation pour la production d'enzymes de biodegradation des agars
CA2354374A1 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
ES2544702T3 (es) * 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
ES2647662T3 (es) * 2009-12-31 2017-12-26 Medigen, Inc. Vacunas de ADN infeccioso frente al virus chikungunya

Also Published As

Publication number Publication date
WO2010008576A3 (en) 2010-04-29
US9968672B2 (en) 2018-05-15
HK1220720A1 (en) 2017-05-12
US20180243404A1 (en) 2018-08-30
ES2902787T3 (es) 2022-03-29
US20140178430A1 (en) 2014-06-26
BRPI0916186B8 (pt) 2021-05-25
EP2310510B1 (en) 2015-05-06
WO2010008576A2 (en) 2010-01-21
BRPI0916186B1 (pt) 2021-03-09
US20110243989A1 (en) 2011-10-06
US10653769B2 (en) 2020-05-19
US8691563B2 (en) 2014-04-08
EP3992296A1 (en) 2022-05-04
EP2977457A3 (en) 2016-05-04
EP2977457B1 (en) 2021-09-01
EP2310510A2 (en) 2011-04-20
EP2310510A4 (en) 2012-01-25
ES2544702T3 (es) 2015-09-02
DK2977457T3 (da) 2021-12-06
BRPI0916186A2 (pt) 2018-05-29
EP2977457A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
US20240366745A1 (en) Tropical disease vaccines
Matić et al. Current view on novel vaccine technologies to combat human infectious diseases
US10653769B2 (en) iDNA vaccines and methods for using the same
Plotkin Vaccines: the fourth century
US8961995B2 (en) Methods and compositions for alphavirus replicons
Tretyakova et al. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine
US10894081B2 (en) Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof
EP4188941A2 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
US12558417B2 (en) Hepatitis A virus preparation method and hepatitis A virus prepared according to method
HK1220720B (en) Idna vaccines and methods for using the same
Pushko et al. Experimental DNA-launched live-attenuated vaccines against infections caused by Flavi-and alphaviruses
CN118853589B (zh) 一种黄热病毒疫苗株3’utr缺失突变体的拯救及在制备减毒活疫苗中的应用
CN120041405A (zh) 一种基于甲病毒复制子的尼帕病毒感染性克隆及其在制备减毒疫苗中的应用